Luminopia scores $16M for virtual reality-based lazy eye treatment
A Cambridge, MA-based biotech has secured another $16 million to expand its digital therapeutic for lazy eye.
Luminopia announced a Series A round on Tuesday from US Venture Partners, Broadfin Advisors, ShangBay Capital and Vertical Group. CEO and co-founder Scott Xiao was inspired by a friend who grew up with amblyopia, better known as lazy eye, which typically develops in early childhood.
“It’s actually a bit of a misnomer in that with patients with amblyopia, there’s actually no structural issues with the eye itself,” Xiao said. “It’s actually a deficiency in the brain and in the visual pathways behind one of the eyes.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.